A Multi-Institutional, Open-Label, Randomized, Phase II Trial Of Ibrutinib In Combination With EGFR Inhibition Or PD-1 Inhibition In Patients With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Ibrutinib (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Mar 2019 Status changed from not yet recruiting to recruiting.
- 18 Sep 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
- 31 Aug 2018 New trial record